An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors
- 1 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Imaging & Biology
- Vol. 14 (3), 336-347
- https://doi.org/10.1007/s11307-011-0500-8
Abstract
The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM).Keywords
This publication has 47 references indexed in Scilit:
- A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growthCancer Immunology, Immunotherapy, 2010
- Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic CancerCancer Biotherapy & Radiopharmaceuticals, 2010
- Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical ResearchCancer Biotherapy & Radiopharmaceuticals, 2009
- Targeted In vivo Imaging of Integrin αvβ6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor ModelCancer Research, 2009
- Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapseBritish Journal of Cancer, 2009
- Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET)Accounts of Chemical Research, 2009
- Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2Bioconjugate Chemistry, 2008
- Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumorsProtein Engineering, Design and Selection, 2008
- Preoperative evaluation of pancreatic adenocarcinomaJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma PatientsClinical Cancer Research, 2008